• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    11/12/24 12:54:20 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 11 )*

                

    Revvity, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    714046109


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 714046109

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital Research Global Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 3,095,316
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 3,099,842
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,099,842 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.5%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Revvity, Inc.
    (b) Address of Issuer's Principal Executive Offices
    940 Winter Street, Waltham, MA 2451
    Item 2.
    (a) Name of Person Filing
    Capital Research Global Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    714046109
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    3,099,842 **
    (b) Percent of Class:
    2.5%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 3,095,316
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 3,099,842
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 3,099,842 shares or 2.5% of the 123,336,708 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.
    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital Research Global Investors
    By: /s/ Donald H. Rolfe
    Date: November 07, 2024
    Name: Donald H. Rolfe
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $RVTY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Revvity Inc.

      10-Q - REVVITY, INC. (0000031791) (Filer)

      5/6/25 4:07:57 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      4/28/25 7:16:22 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 8-K filed by Revvity Inc.

      8-K - REVVITY, INC. (0000031791) (Filer)

      4/25/25 4:06:40 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Financials

    Live finance-specific insights

    See more
    • Revvity Announces Financial Results for the First Quarter of 2025

      Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu

      4/28/25 6:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity Board Declares Quarterly Dividend

      The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec

      4/24/25 4:05:00 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity to Hold Earnings Call on Monday, April 28, 2025

      Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows

      4/3/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Vandebroek Sophie V. was granted 2,412 shares, increasing direct ownership by 90% to 5,088 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/1/25 4:05:18 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Klobuchar Michael A was granted 2,412 shares, increasing direct ownership by 90% to 5,088 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/1/25 4:05:13 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Chapin Samuel R. was granted 2,412 shares, increasing direct ownership by 13% to 20,396 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/1/25 4:05:19 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Revvity upgraded by UBS with a new price target

      UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

      5/1/25 7:42:49 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity downgraded by Bernstein with a new price target

      Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

      1/10/25 8:41:17 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity upgraded by BofA Securities with a new price target

      BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

      12/13/24 8:43:02 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AstroNova Sends Letter to Shareholders Highlighting Growth Strategy and Strength of Board

      AstroNova is at critical inflection point in its strategic progress to create meaningful competitive advantages for the Product Identification segment and drive strong, sustainable growth, improved profitability and address measurably larger addressable markets Askeladden/Patel's misguided, upstart campaign is disrupting progress and his unfit nominees stand to siderail advancement Urges shareholders to vote "FOR" ONLY AstroNova's Board nominees on the WHITE proxy card Current leadership has transformed AstroNova's capabilities, product mix, and scale, delivering 7.5% compound annual revenue growth since Gregory Woods' appointment as CEO AstroNova, Inc. (NASDAQ:ALOT), a leading innovat

      5/19/25 5:00:00 PM ET
      $ALNT
      $ALOT
      $BWA
      $RVTY
      Electrical Products
      Industrials
      Computer peripheral equipment
      Technology
    • Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

      The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer's disease and therapeutic drug monitoring Revvity, Inc. (NYSE:RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously ru

      5/19/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity to Present at Upcoming Investor Conferences

      Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will b

      4/30/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 4:30:07 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:28:28 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Revvity Inc.

      SC 13G - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:22:34 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials